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Abstract
Background: Overweight and weight gain throughout adult life have been associated with increased risk of breast
cancer after the menopause. However the role of body weight at a young age and of the timing of weight gain
over the lifetime in postmenopausal breast cancer is not well documented.
Methods: We conducted a population-based case-control study on breast cancer in France that included 739 cases
and 815 population controls in postmenopausal women. Height, weight at age 20, 40 and 50 as well as weight one
year before diagnosis were obtained during in-person interviews.
Results: No association between body mass index at the age of 20 years and breast cancer after the menopause
was detected. However, we found that postmenopausal breast cancer was associated with weight gain between
ages 40 and 50 years (OR per 5 kg/m2 increase in BMI: 1.45 [95%ci 1.06−1.98]). The increased risk of breast cancer
associated with weight gain was more consistent in leaner women at age 20, in older postmenopausal women
(>65 years), and in women who did not use menopausal hormone therapy.
Conclusions: These findings point to the importance of controlling for weight gain in middle aged-women.
The role of low body weight in young adulthood in breast cancer risk after the menopause should be further
scrutinized.
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Background
With over 1.5 million new cases each year across the
world, breast cancer is the leading cause of cancer among
women. Despite a recent decrease attributed to the reduc-
tion of menopausal hormone therapy, incidence rates of
postmenopausal breast cancer in wealthy countries has
grown steadily over the last decades. Rising incidence rates
are also observed in emerging countries as high calorie
intake and sedentary life become more common, pointing
to the role of overweight and lack of physical activity as
major modifiable causes of breast cancer among postmeno-
pausal women.
The relationship between adiposity and breast cancer
is complex and varies during lifetime. Before menopause,
adiposity reduces the risk of breast cancer. This inverse
association has been attributed to a decreased number
of ovulations in overweight women and alteration of
circulating hormone levels, which play a key role in
breast cancer etiology, but other mechanisms may also
account for the protective effect of high BMI before the
menopause [1]. After the menopause, a high BMI
increases the risk of breast cancer breast cancer, and this
association is explained by estradiol production in the
adipose tissue [2–4].
Investigating weight changes during lifetime, particu-
larly in the period around the menopause, when the
effect of BMI in breast cancer changes from a protective
to a deleterious effect, is thus important to improve our
understanding of the relationship between adiposity and
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breast cancer. However, most studies on breast cancer
among postmenopausal women have only measured
weight gain over long periods, usually from early adult-
hood to the time of cancer diagnosis, making difficult to
evaluate how weight changes in specific periods of life
may affect breast cancer risk [5–8].
Elevated BMI during childhood or adolescence has
also been associated with a decreased risk of postmeno-
pausal breast cancer in some studies [9–11]. It has been
postulated that leanness in early adulthood may increase
the risk of postmenopausal breast cancer due to incom-
plete differentiation of mammary gland cells related to
insufficient mammary fat pad or progesterone deficiency
[6, 12]. This association, however, should be scrutinized.
In order to clarify the relationship between postmeno-
pausal breast cancer risk and lifetime weight history, we
used the data of a large population-based case-control
study in France, focusing on the timing of weight
changes over the lifetime and on the role of low weight
(BMI <18.5 kg/m2) at a young age.
Methods
The CECILE study is a population-based case-control
study in Côte d'Or and Ille-et-Vilaine, two French
administrative areas (départements) located in Eastern
and Western part of France, respectively.
Recruitment of cases and controls
The case group included incident cases of in situ or
invasive breast cancer diagnosed between April 2005
and March 2007 in women aged 25–75 years who
resided in the study areas. Patients were recruited in the
main cancer hospital in each area (Centre Eugène
Marquis in Rennes and Centre Georges-François Leclerc
in Dijon), as well as from smaller public and private
hospitals that also recruited breast cancer patients.
Among the 1553 eligible cases identified during the
study period, 163 refused to participate, 151 could
not be contacted, and 7 died before the interview,
leaving 1232 cases included in the study sample
(participation 79.3 %).
Controls were women without a previous history of
breast cancer recruited in the general population of each
study area. They were selected by phone and were
frequency-matched to the cases by 10-year age group.
To avoid selection bias that could arise from differential
participation rates across categories of socioeconomic
status (SES), we obtained a control group with a distri-
bution by SES category similar to the general population,
by using predefined numbers of controls by SES calcu-
lated from the census data. To recruit the controls,
phone numbers of private homes were selected at
random from the telephone directory completed before-
hand with unlisted numbers. Phone numbers were
dialed up to 15 times at different times of the day and
different days of the week until contact could be estab-
lished with the residents. When a woman was living in
the residence reached by phone, she was invited to
participate to the study, as long as the predefined
number of controls in her age and SES stratum was not
complete. When this number was exceeded, the woman
was excluded. To obtain the desired number of controls
within the limits of age and SES categories, approxi-
mately 30,000 phone numbers were dialed for identifying
1,731 eligible controls. Among 1731 controls identified
by telephone fulfilling eligibility criteria, 260 declined
participation and 154 could not be re-contacted for an
in-person interview, leaving 1317 women available for
the study (participation 76.1 %).
The study was approved by the French Ethic
Committee (CCPPRB Kremlin-Bicêtre, Jan 2005), the
National Data Protection Agency (Dec 2004) and the
Advisory Committee on the Treatment of Health
Research Information (Apr 2004). All participants
signed informed consent.
Selection of study subjects
Only postmenopausal women were included in the
analysis. Women were considered postmenopausal if
they had not menstruated for twelve or more months
(natural menopause, n = 936), if they had had bilateral
oophorectomy (artificial menopause, n = 93), or if they
had used MHT (Menopausal Hormone Therapy)
before natural cessation of menstruation (n = 352).
Women with unknown menopausal status (n = 199)
(hysterectomy before cessation of menstruations or
unknown date of last menstruation), were considered
postmenopausal if they were aged 50 or more years,
the median age at menopause in women with natural
menopause (n = 174). Women with unknown meno-
pausal status below 50 years old were excluded from
the analysis (n = 25). One woman reporting aberrant
low weight was excluded from the analysis. In total,
the analysis included 1554 postmenopausal women
(739 cases and 815 controls).
Data collection
Data pertaining to study subjects were obtained from a
structured questionnaire during in-person interviews
conducted by trained interviewers. We defined a reference
date for each study subject, which was the date of diagnosis
for the cases and the date of selection for the controls. The
age at reference date will be referred to below as current
age. Only events that occurred before that date were
considered in the analyses. We elicited information on
socio-demographic characteristics, history of previous
diseases, family history of cancer, history of menstruations,
use of oral contraceptives, infertility, reproductive history,
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residential and occupational history, lifetime consumption
of alcohol and tobacco, recreational activities, and dietary
habits.
Women were invited to report their height at the age
of 20 years, and to report their usual weight one year
before reference date (hereinafter referred to as current
weight) to avoid reporting weight loss that might be due
to cancer development. We also elicited information on
weight at the ages of 20, 40 and 50 years.
Information on estrogen (ER) and progesterone receptor
(PR) status was obtained from the pathology report.
Tumors containing more than 10 % positive cells for
hormonal receptors were classified as receptor-positive.
Statistical analysis
Odds ratios (ORs) of breast cancer were calculated for BMI
at age 20, BMI at age 50 and BMI at the current age, and
for BMI changes from age 20 to current age, from age 20
to 40, from age 40 to 50, and from age 50 to current age.
BMIs were calculated as weight in kilograms divided by
height in meters squared (kg/m2). BMI at different ages
were categorized according to the WHO classification
(<18.5; 18.5–25; 25–30; ≥30 kg/m2), except for BMI at age
20 where we used a single category of BMI ≥ 25 kg/m2 due
to small number of young obese women ≥30 kg/m2. BMI
changes during different periods of life were categorized in
3 groups. To enable comparisons between BMI gain during
different periods of life, and despite uneven distributions,
we sought to use the same cut points for defining BMI gain
categories in different periods: BMI gain <1 kg/m2; BMI
gain ≥ 1 < 3 kg/m2; and BMI gain ≥ 3 kg/m2. For BMI
changes from age 20 to current age, the highest category of
BMI gain was subdivided in two classes (3–6 kg/m2 and ≥
6 kg/m2). We also fitted models using tertiles or quartiles
of BMI gain distribution among controls specific to each
exposure period, but the findings were very similar and are
not shown. To test dose-response trends, we fitted models
where BMI at different ages and BMI changes were intro-
duced as continuous variables, assuming a linear relation-
ship between the variable and breast cancer risk, and
reported odds ratios for each increment of 5 kg/m2 of BMI
or BMI change.
Further analyses were conducted to examine whether
low BMI at age 20 (<18.5; ≥ 18.5 kg/m2), age at reference
date (<65, ≥ 65 years), and use of menopausal hormone
therapy (MHT) (current vs past or never) modified the
association of breast cancer with BMI at different ages,
and BMI changes. In these analyses, we present only the
odds ratios associated with continuous variables for BMI
and BMI changes. p-values for interaction between BMI
or BMI changes and the stratification variables (i.e. BMI
at age 20 years, age at reference date and MHT use)
were calculated by comparing models with and without
an interaction term using the likelihood ratio test.
Odds ratios and 95 % confidence intervals were calcu-
lated using unconditional logistic regression models
adjusting for the matching variables, i.e. age (5-year age
group) and study area, and for breast cancer risk factors
in Table 1: age at menarche (≤11, 12, 13, 14, ≥ 15 years),
parity (0, 1, 2, 3, ≥ 4 children), age at first full-term preg-
nancy (<22, 22–24, 25–27, ≥ 28 years), duration of
breast-feeding (0, <26, 26–52, >52 weeks), oral contra-
ceptive use (ever, never), family history of breast cancer
in first degree relatives (yes, no), MHT use (current,
never or past use), recreational physical activity (ever/
never), tobacco smoking (never, < 10, ≥ 10 packs-years),
and alcohol consumption (≤3, 4–7, 8–14, > 14 glasses
per week).
All analyses were also conducted using different
categorization for BMI and BMI gain during lifetime, or
using weight and weight changes (in kg) instead of BMI.
These analyses produced similar findings and are not
reported here. We also conducted analyses stratifying
the case group according to hormone receptor status of the
tumor (ER-positive/ER-negative, PR-positive/PR-negative)
using polytomous logistic regression models, but no
particular hint emerged from this analysis (not shown).
All analyses were conducted using SAS computer
software (version 9.3, Cary, North Carolina).
Results
Selected characteristics of cases and controls are shown
in Table 1. As expected from frequency-matching, the
distributions by age and study area were similar for cases
and controls. Breast cancer was associated with family
history of breast cancer in first-degree relatives, early
age at menarche, low parity, late age at first full-term
pregnancy, current use of MHT, height and physical
activity. Cases and controls did not differ in our data
with respect to duration of breastfeeding, age at meno-
pause, alcohol or tobacco consumption.
Table 2 shows mean BMI at age 20, mean BMI at age 50
and mean BMI changes between ages 20 and 40, 40 − 50
and 50 to current age after stratification of the control
group by category of current BMI. There was a clear trend
of higher BMI at ages 20 and 50 and of higher BMI gain
as current BMI becomes higher. Table 2 also shows the
Pearson’s correlation coefficients with current BMI. Corre-
lations were moderate for BMI at age 20 and BMI change
between ages 40 and 50 (Pearson’s r = 0.32), intermediate
for BMI changes between ages 20 and 40 and BMI
changes between age 50 and current age (Pearson’s r =
0.54 and 0.55, respectively), and strong for BMI at age 50
(Pearson’s r = 0.79).
After adjustment for potential confounders listed in
Table 1, BMI at age 20, BMI at age 50 and current BMI
were not found to be associated with postmenopausal
breast cancer (Table 3). However, BMI gain between 40
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and 50 years of age was associated with increased risk of
breast cancer (OR per 5 kg/m2 BMI gain between ages
40 and 50: 1.32; 95 % ci 1.05–1.65). Further adjustment
for current BMI did not modify this finding. No associ-
ation was observed with BMI gain before 40 and after
50 years of age. Models were also fitted using weight
changes in kg instead of BMI in kg/m2. The results are
shown in Additional file 1: Table S1 and yielded similar
conclusions.
Results of the stratification of BMI and BMI gain
variables by BMI at age 20 (<18.5 kg/m2; ≥18.5 kg/m2),
current age (<65 years; ≥65 years), and MHT use
(current users; non-current users) are shown in Table 4.
The stratification by BMI at age 20 showed that among
leaner women at age 20 (BMI 20 < 18.5 kg/m2), the odds
ratios for each increment of 5 kg/m2 of current BMI
(OR 1.47; 95 % ci 1.05–2.07) and of BMI-gain between
ages 40 and 50 (OR 2.06; 95 % ci 1.09–3.88) were mark-
edly higher than the corresponding odds ratios in
women with BMI at age 20 ≥ 18.5 kg/m2. However the
p-values for interaction between BMI at age 20 and
current BMI or BMI gain were not statistically signifi-
cant (p interaction 0.14 and 0.40, respectively). The
stratification by current age showed higher odds ratios
for BMI at age 50, current BMI and BMI gain between
Table 1 Distribution of cases and controls by age, study area
and selected risk factors of breast cancer
Cases (n = 739) Controls (n = 815) ORa 95 % CI
N % N %
Study area (département)
Côte d'Or 235 31.8 284 34.8
Ille-et-Vilaine 504 68.2 531 65.2
Age at reference date (years)
35-39 0 0.0 1 0.1
40-44 1 0.1 1 0.1
45-49 18 2.4 33 4.1
50-54 103 13.9 109 13.4
55-59 189 25.6 192 23.6
60-64 158 21.4 164 20.1
65-69 147 19.9 192 23.6
70-74 123 16.6 123 15.1
Family history of breast cancer in first degree relatives
No 604 81.7 715 87.7 1 ref
Yes 135 18.3 100 12.3 1.62 [1.22-2.16]
Age at menarche (years)
≤ 11 131 18 122 15.2 1 ref
12 179 24.7 172 21.4 0.98 [0.71-1.35]
13 155 21.3 174 21.6 0.82 [0.59-1.15]
14 143 19.7 165 20.5 0.81 [0.58-1.13]
≥ 15 118 16.3 172 21.4 0.63 [0.45-0.89]
Parity
Nulliparous 79 10.7 50 6.1 1 ref
1 FTPb 109 14.7 113 13.9 0.61 [0.39-0.95]
2 FTP 279 37.8 270 33.1 0.65 [0.44-0.96]
3 FTP 183 24.8 245 30.1 0.46 [0.31-0.69]
≥ 4 FTP 89 12 137 16.8 0.41 [0.26-0.64]
Age at first FTP among parous women (years)
< 22 185 28 252 32.9 1 ref
22-24 196 29.7 252 32.9 1.07 [0.82-1.40]
25-27 141 21.4 167 21.8 1.16 [0.86-1.56]
> 27 138 20.9 94 12.3 2.02 [1.46-2.81]
Breastfeeding among parous women (weeks)
never 349 53.5 399 52.2 1 ref
< 26 224 34.4 261 34.2 1.03 [0.82-1.31]
26-52 54 8.3 67 8.8 0.97 [0.66-1.43]
> 52 25 3.8 37 4.8 0.82 [0.48-1.40]
Age at menopause (years)c
< 48 105 22.7 115 22.9 1 ref
48-50 136 29.4 157 31.2 0.85 [0.59-1.23]
51-53 133 28.8 126 25 1.03 [0.71-1.50]
≥ 54 88 19 105 20.9 0.82 [0.54-1.23]
Table 1 Distribution of cases and controls by age, study area
and selected risk factors of breast cancer (Continued)
Current MHT use
No 589 79.7 690 84.7 1 ref
Yes 150 20.3 125 15.3 1.44 [1.10-1.88]
Height (cm)
< 158 187 25.4 230 28.2 1 ref
158-161 188 25.5 198 24.3 1.25 [0.94-1.67]
162-165 172 23.3 223 27.4 1.03 [0.77-1.38]
≥ 166 190 25.8 164 20.1 1.63 [1.21-2.20]
Alcohol consumption (glasses per week)
≤ 3 542 73.3 581 71.3 1 ref
4-7 108 14.6 122 15.0 0.92 [0.69-1.22]
8-14 53 7.2 71 8.7 0.77 [0.52-1.12]
> 14 36 4.9 41 5.0 0.91 [0.57-1.45]
Tobacco (pack-years)
Never 500 68.3 563 70.2 1 ref
< 10 119 16.3 134 16.7 1.03 [0.77-1.36]
≥ 10 113 15.4 105 13.1 1.28 [0.95-1.74]
Physical activity
No 269 36.8 264 32.5 1 ref
Yes 462 63.2 548 67.5 0.83 [0.67-1.02]
aOdds ratios adjusted for age at reference date and study area
bFTP: Full-Term Pregnancy
cAge at menopause unknown in 227 cases and 312 controls
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40 and 50 years in women ≥ 65 years than in women
<65 years, with p-values for interaction 0.07, 0.08 and
0.08, respectively. Finally, the stratification on MHT use
showed that the odds ratio for BMI gain between ages
40 and 50 was 1.37 (95 % ci 1.08–1.74) in MHT non-
users whereas it was 1.02 (95 % ci 0.47–2.20) in current
users (p-value for interaction 0.34).
Analyses were also conducted by tumor subtypes defined
according to hormonal receptor status (ER-positive, ER-
negative, PR-positive, PR-negative). No difference between
tumor subtypes was observed (data not shown).
Discussion
We found that weight gain in the age range period 40–
50 years, but not in earlier periods of life, was associated
with increased risk of postmenopausal breast cancer.
Conversely, our data do not confirm that postmeno-
pausal breast cancer risk is increased in women with low
BMI at a young age. However, the association between
weight gain between 40 and 50 and postmenopausal
breast cancer risk, was more consistent among leaner
women at the age of 20, among older women (≥65 years
at diagnosis) and among non-MHT users. These findings
point to the importance of examining weight history
over the lifetime to clarify the relationships between
adiposity and breast cancer risk after the menopause.
Weight gain
BMI gain in adulthood has been linked to the risk of
postmenopausal breast cancer in previous investigations
[5, 8, 10, 13]. Although the timing of weight gain during
life may be an important determinant of breast cancer
risk, epidemiological evidence is sparse since most
studies have assessed weight gain over long periods from
early adulthood to the time of cancer diagnosis regard-
less of specific time periods [5, 8, 9, 14]. Our results
suggest that weight gain during the age range period
40–50 years, i.e. in late reproductive period, may be
particularly harmful. These findings are consistent with
studies that reported increased risk of breast cancer
among women who gained weight in middle adult-
hood [15, 16]. If this is confirmed, it would point to
the importance of controlling weight gain in that
period of life.
We also observed that the association of breast cancer
with current BMI and weight or BMI gain in the age
range period 40–50 years was stronger in women above
65 years of age than in younger postmenopausal women,
suggesting a relatively long induction period between
weight gain and breast cancer occurrence. Alternatively,
it is possible that the beneficial effect of adiposity during
pre-menopause may compensate the adverse effect of
overweight in early post-menopause.
Weight in early adulthood
The hypothesis that weight during adolescence or young
adulthood may influence breast cancer risk after the meno-
pause is supported by several epidemiological studies
reporting an inverse association between weight at a young
age and postmenopausal breast cancer [9–11, 17, 18]. In
addition, it was demonstrated that pre-pubertal girls with
low weight have higher mammographic density when they
become adults [19], and mammographic density is one of
the strongest risk factors for breast cancer [20]. It was also
postulated that low level of adiposity in the mammary gland
may alter breast tissue maturation, making breast tissue
more susceptible to carcinogenic stimuli among leaner
women [6, 21]. Our data did not confirm the hypothesis of
a direct link between low weight at a young age and breast
cancer risk after menopause, as no association between
BMI at age 20 and postmenopausal breast cancer was
detected. However, there was weak indication that weight
gain between age 40 and 50 might lead to higher post-
menopausal breast cancer risk in women who were leaner
at a young age (BMI < 18.5 kg/m2). This finding should be
interpreted with care as no statistically significant inter-
action between BMI at age 20 and BMI gain was seen.
Nevertheless, it is consistent with a report from the large
Table 2 Mean values of BMI at different ages and of BMI changes by categories of current BMI among controls
Current BMI (kg/m2)
<25 25-30 ≥30 pa Pearson rb
(n = 428) (n = 245) (n = 141)
Mean current BMI (kg/m2) (sd) 22.0 (1.9) 27.2 (1.4) 34.2 (4.2) <10-4 1.00
Mean BMI at age 50 (kg/m2) (sd) 21.4 (2.3) 24.7 (2.6) 29.8 (4.6) <10-4 0.79
Mean BMI at age 20 (kg/m2) (sd) 20.1 (2.3) 20.9 (2.6) 22.5 (3.2) <10-4 0.32
Mean BMI change from age 20 to current age (kg/m2) (sd) 1.9 (2.8) 6.3 (2.9) 11.8 (5.1) <10-4 0.86
Mean BMI change from age 20 to 40 (kg/m2) (sd) 0.6 (2.4) 2.3 (2.3) 4.6 (4.7) <10-4 0.54
Mean BMI change from age 40 to 50 (kg/m2) (sd) 0.6 (1.7) 1.5 (2.2) 2.9 (4.4) <10-4 0.32
Mean BMI change from age 50 to current age (kg/m2) (sd) 0.6 (2.0) 2.5 (2.5) 4.5 (4.7) <10-4 0.55
aP-value of ANOVA
bPearson correlation coefficient with current BMI
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US Nurse’s Health Study showing that the association of
postmenopausal breast cancer risk with weight gain of
25 kg or more since the age 18 years was stronger in
women with BMI below 21 kg/m2 at age 18 years than in
heavier women (p for interaction 0.05) [13]. This result
points to the importance of examining lifelong weight
history in order to elucidate the complex relationships
between adiposity and breast cancer risk.
Current MHT use
The association of postmenopausal breast cancer risk with
weight gain between ages 40 and 50 years was apparent
only among non-current MHT users, although the inter-
action between BMI gain and MHT use was not signifi-
cant. This is consistent with several studies that reported
an association between adiposity and postmenopausal
breast cancer only among women who did not use MHT
[5, 6, 8, 10, 13, 18, 22–24]. To explain this frequent obser-
vation, it has been suggested that the increased levels of
circulating estrogens in women treated with hormones are
predominant and mask the effects of adiposity on breast
carcinogenesis [25].
Study strengths and limits
In our study, incident breast cancers were identified
on a population basis in well-defined geographical
areas, using inclusion criteria similar to a cancer
registry, and using active real-time search in the main
cancer hospitals in each area. Controls were carefully
selected from the study base controlling for possible
differential participation rates across SES categories.
In addition, all potentially important confounders
were taken into account in the analysis.
The main limitations of the study include the self-
reported and recalled history of height and weight. Studies
that examined the accuracy of self-reported height and
weight compared to measured values consistently reported
that height tended to be overestimated and weight to be
underestimated by the women [26–28]. If this applies to
our study, then BMI values should be underestimated.
Errors due to recalled weight at younger ages are also likely
to have occurred, particularly for longer recall [29]. How-
ever, we think that misclassification errors due to self-
reported or recalled weight were most likely non-
differential, and are not probable explanations for the
observed associations. Indeed, the cases and the controls
were interviewed in the same way using a standardized
questionnaire, they were not aware of the specific objectives
of the study, and the possible link of weight changes with
breast cancer is not a widely known fact among women in
France. Moreover the main findings of our study were in
line with expectations. As in other studies, chance findings
may have occurred especially as we performed a large
number of tests. Conversely some associations may have
Table 3 Odds ratios of postmenopausal breast cancer for BMI at
age 20, age 50 and current age, and for BMI gain from age 20 to
current age, age 20 to 40, age 40 to 50, and age 50 to current age
par category and per increment of 5 kg/m2 of BMI or BMI gain
Cases Controls ORa 95 % CI p trendb
(n = 739) (n = 815)
N % N %
BMI at age 20 (kg/m2)
< 18.5 146 20.3 150 19.0 1.10 [0.84-1.44]
≥ 18.5 < 25 527 73.2 587 74.2 1 ref
≥ 25 47 6.5 54 6.8 0.92 [0.60-1.41]
Per 5 kg/m2 1.03 [0.85-1.25] 0.76
BMI at age 50 (kg/m2)
< 18.5 34 4.9 29 3.8 1.14 [0.67-1.96]
≥ 18.5 < 25 461 65.8 510 66.6 1 ref
≥ 25 < 30 147 21.0 162 21.1 1.07 [0.81-1.40]
≥ 30 59 8.4 65 8.5 1.05 [0.70-1.56]
Per 5 kg/m2 1.07 [0.94-1.22] 0.30
Current BMI (kg/m2)
< 18.5 15 2.0 21 2.6 0.73 [0.36-1.50]
≥ 18.5 < 25 374 50.7 407 50.0 1 ref
≥ 25 < 30 223 30.3 245 30.1 1.03 [0.80-1.31]
≥ 30 125 17.0 141 17.3 1.04 [0.77-1.41]
Per 5 kg/m2 1.03 [0.92-1.14] 0.62
BMI change from age 20 to current age (kg/m2)
< 1 139 19.3 161 20.4 1 ref
≥ 1 < 3 140 19.4 136 17.2 1.18 [0.83-1.66]
≥ 3 < 6 196 27.2 211 26.7 1.10 [0.81-1.51]
≥ 6 245 34.0 283 35.8 1.06 [0.78-1.44]
Per 5 kg/m2 1.02 [0.91-1.14] 0.76
BMI change from age 20 to 40 (kg/m2)
< 1 306 44.0 338 43.8 1 ref
≥ 1 < 3 240 34.5 232 30.1 1.22 [0.95-1.57]
≥ 3 150 21.6 202 26.2 0.88 [0.66-1.16]
Per 5 kg/m2 0.88 [0.74-1.06] 0.18
BMI change from age 40 to 50 (kg/m2)
< 1 329 48.2 396 52.7 1 ref
≥ 1 < 3 223 32.7 234 31.2 1.18 [0.92-1.51]
≥ 3 131 19.2 121 16.1 1.45 [1.06-1.98]
Per 5 kg/m2 1.32 [1.05-1.65] 0.02
BMI change from age 50 to current age (kg/m2)
< 1 310 44.2 321 41.9 1 ref
≥ 1 < 3 212 30.2 240 31.3 0.95 [0.73-1.23]
≥ 3 179 25.5 205 26.8 0.97 [0.73-1.29]
Per 5 kg/m2 1.00 [0.83-1.21] 0.97
aOdds ratio adjusted for study area, age at reference date, age at menarche,
parity, age at first full-term pregnancy, breastfeeding, family history of breast
cancer, oral contraceptive use, current use of MHT, alcohol consumption,
tobacco smoking, and physical activity
bp for trend calculated from the model using BMI or BMI change as
continuous variables
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remained undetected due to low statistical power in some
analyses. In particular, statistical power was limited to
detect interactions between variables. With these limita-
tions in mind, however, we believe that these data are of
valuable interest given the scarcity of studies examining the
effect of BMI assessed over the lifetime on breast cancer
risk, and provide further opportunities for research.
Conclusion
Weight history throughout life appears to be a key deter-
minant of breast cancer risk after the menopause, but
interplay between age, weight, weight gain and breast
cancer risk factors appears to be complex. Our findings
point to the importance of controlling for weight gain in
middle aged-women. The role of low body weight during
early adulthood in postmenopausal breast cancer risk
should be examined further.
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Additional file 1: Table S1. Odds ratios of postmenopausal breast
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